The FDA has approved Arcutis Biotherapeutics' ZORYVE cream 0.3% for treating plaque psoriasis in children aged 2 and older. This once-daily, non-steroidal topical treatment is safe, effective, and can be used on sensitive skin areas without duration limits. The approval addresses a significant treatment gap for young children with this chronic skin condition, offering a steroid-free alternative where options were previously limited. ZORYVE has now received seven FDA approvals in four years, reflecting Arcutis' commitment to pediatric dermatology innovation.
Plum Acquisition Corp. IV has postponed its extraordinary general meeting of shareholders from July 2 to July 10, 2026, to allow more time for shareholder engagement. Consequently, the deadline for shareholders to submit redemption requests has been ...
The U.S. Supreme Court ruled in Chatrie v. U.S. that government collection of location data via geofence warrants constitutes a search under the Fourth Amendment. This decision overturns a lower court ruling and requires further review of whether the...
The KraneShares CSI China Internet ETF (KWEB) provides focused exposure to leading Chinese internet and AI companies and is currently trading near its 52-week lows. The ETF benefits from strong AI-driven growth, government support, and attractive val...
DBV Technologies is preparing to submit a Biologics License Application (BLA) for its VIASKIN® Peanut patch aimed at children aged 4 to 7 years. The company has engaged in detailed discussions with the FDA to ensure a thorough and efficient review pr...
Devonian Health Group Inc. reported a net loss of $1.9 million for the quarter ended April 30, 2026, an improvement from the previous year's loss due to reduced impairment charges. The company remains debt-free with $0.7 million in cash and is focusi...
